NCT03106779 · OUTCOME

Major Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: by Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 & 156, Overall

What was measured

MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR. Overall time point has the count indicating participants achieving MMR at any time during the study.

Analysis population: Full Analysis Set (FAS): The FAS comprised of all randomized participants.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Bosutinib

Participants randomized to bosutinib 500mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Asciminib	157
Bosutinib	76

Reported measurements

by Week 4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	3	Not reported	Not reported	Not reported	Not reported
Bosutinib	0	Not reported	Not reported	Not reported	Not reported

by Week 8

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	12	Not reported	Not reported	Not reported	Not reported
Bosutinib	4	Not reported	Not reported	Not reported	Not reported

by Week 12

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	30	Not reported	Not reported	Not reported	Not reported
Bosutinib	7	Not reported	Not reported	Not reported	Not reported

by Week 16

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	39	Not reported	Not reported	Not reported	Not reported
Bosutinib	8	Not reported	Not reported	Not reported	Not reported

by Week 24

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	43	Not reported	Not reported	Not reported	Not reported
Bosutinib	11	Not reported	Not reported	Not reported	Not reported

by Week 36

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	51	Not reported	Not reported	Not reported	Not reported
Bosutinib	13	Not reported	Not reported	Not reported	Not reported

by Week 48

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	55	Not reported	Not reported	Not reported	Not reported
Bosutinib	15	Not reported	Not reported	Not reported	Not reported

by Week 60

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	60	Not reported	Not reported	Not reported	Not reported
Bosutinib	16	Not reported	Not reported	Not reported	Not reported

by Week 72

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	60	Not reported	Not reported	Not reported	Not reported
Bosutinib	17	Not reported	Not reported	Not reported	Not reported

by Week 84

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	63	Not reported	Not reported	Not reported	Not reported
Bosutinib	17	Not reported	Not reported	Not reported	Not reported

by Week 96

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	67	Not reported	Not reported	Not reported	Not reported
Bosutinib	18	Not reported	Not reported	Not reported	Not reported

by Week 108

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	67	Not reported	Not reported	Not reported	Not reported
Bosutinib	18	Not reported	Not reported	Not reported	Not reported

by Week 120

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	68	Not reported	Not reported	Not reported	Not reported
Bosutinib	18	Not reported	Not reported	Not reported	Not reported

by Week 132

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	70	Not reported	Not reported	Not reported	Not reported
Bosutinib	18	Not reported	Not reported	Not reported	Not reported

by Week 144

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	71	Not reported	Not reported	Not reported	Not reported
Bosutinib	18	Not reported	Not reported	Not reported	Not reported

by Week 156

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	71	Not reported	Not reported	Not reported	Not reported
Bosutinib	18	Not reported	Not reported	Not reported	Not reported

Overall

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Asciminib	74	Not reported	Not reported	Not reported	Not reported
Bosutinib	19	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
3
group Id
OG001
value
0
title
by Week 4
categories
measurements
group Id
OG000
value
12
group Id
OG001
value
4
title
by Week 8
categories
measurements
group Id
OG000
value
30
group Id
OG001
value
7
title
by Week 12
categories
measurements
group Id
OG000
value
39
group Id
OG001
value
8
title
by Week 16
categories
measurements
group Id
OG000
value
43
group Id
OG001
value
11
title
by Week 24
categories
measurements
group Id
OG000
value
51
group Id
OG001
value
13
title
by Week 36
categories
measurements
group Id
OG000
value
55
group Id
OG001
value
15
title
by Week 48
categories
measurements
group Id
OG000
value
60
group Id
OG001
value
16
title
by Week 60
categories
measurements
group Id
OG000
value
60
group Id
OG001
value
17
title
by Week 72
categories
measurements
group Id
OG000
value
63
group Id
OG001
value
17
title
by Week 84
categories
measurements
group Id
OG000
value
67
group Id
OG001
value
18
title
by Week 96
categories
measurements
group Id
OG000
value
67
group Id
OG001
value
18
title
by Week 108

denoms

counts
group Id
OG000
value
157
group Id
OG001
value
76
units
Participants

description

groups

description
Participants randomized to asciminib 40mg BID
id
OG000
title
Asciminib
description
Participants randomized to bosutinib 500mg QD
id
OG001
title
Bosutinib

param Type

COUNT_OF_PARTICIPANTS

population Description

Full Analysis Set (FAS): The FAS comprised of all randomized participants.

reporting Status

POSTED

time Frame

by Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 & 156, Overall

title

Major Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice